How the Flyte device revolutionizes SUI management

In a recent interview with Contemporary OB/GYN, Wanda Filer, MD, MBA FAAFP, from Pelvital, discussed the benefits of the Flyte device for managing stress urinary incontinence (SUI).

The Flyte device is an innovative treatment for SUI that uses mechanotherapy, a novel approach distinct from electrical stimulation or biofeedback. The device consists of an intravaginal wand that delivers gentle pulsing to the vaginal wall for 5 minutes a day over a 6-week period.

This at-home treatment, prescribed by health care providers and obtained through durable medical equipment, has shown remarkable efficacy, achieving results comparable to surgery. Patients with mild to severe SUI can benefit, with many experiencing complete dryness. The effects of the treatment last for at least 2 years, and if symptoms return because os factors such as childbirth or weight gain, patients can reuse the device to restore its benefits.

Mechanotherapy strengthens the pelvic floor muscles, and the Flyte device can be prescribed by various healthcare professionals, including family medicine doctors, OB-GYNs, urogynecologists, and pelvic floor physical therapists. Expanding SUI treatment involves identifying and addressing patients who suffer in silence. Many women face barriers to care, such as transportation issues, childcare responsibilities, and financial concerns. Additionally, for those who have experienced sexual trauma, the Flyte device offers a private and empowering treatment option.

Screening for SUI is crucial as it significantly impacts women's confidence and quality of life. Many affected individuals withdraw from social activities, exercise, and dating because of fear of leakage, embarrassment, and odor. The Flyte device has helped thousands of women regain their self-esteem and return to normal activities. According to Filer, increasing awareness and accessibility to this treatment can improve the lives of many suffering from SUI.

This video is part 2 of a 2-part series. Click here for part 1.

Reference

Pelvital announces pivotal article highlighting efficacy of transvaginal mechanotherapy as first-line treatment for stress urinary incontinence. Pelvital. February 12, 2025. Accessed March 14, 2025. https://www.prweb.com/releases/pelvital-announces-pivotal-article-highlighting-efficacy-of-transvaginal-mechanotherapy-as-first-line-treatment-for-stress-urinary-incontinence-302374521.html.